Rezera Inc. is expected to list on NASDAQ on 2026-11-12 under the symbol RZRA, with shares priced in a $11.00 to $13.00 range. The company is offering 16,666,667 shares in a clinical-stage biotech IPO built around oral NLRP3 inhibitors.
The bull case is a large unmet need in PAD and a pipeline with strategic backers; the bear case is that Rezera has no revenue, no approved product, and a long clinical path ahead.
Rezera Inc. is expected to list on NASDAQ on 2026-11-12 under the symbol RZRA, with shares priced in a $11.00 to $13.00 range. The company is offering 16,666,667 shares in a clinical-stage biotech IPO built around oral NLRP3 inhibitors.
The bull case is a large unmet need in PAD and a pipeline with strategic backers; the bear case is that Rezera has no revenue, no approved product, and a long clinical path ahead.
Quick Facts
Expected listing date: November 12, 2026
Exchange: NASDAQ
Proposed symbol: RZRA
Price range: 11.00 - 13.00
Shares offered: 16.67M shares
Status: Expected
Company Overview
Rezera Inc. is a clinical-stage biotechnology company developing a portfolio of internally invented, proprietary, wholly owned oral NLRP3 inhibitors. Its lead program is ruvonoflast, and its second program is trabzanoflast. NLRP3 is described in the filing as an upstream driver of sterile inflammation and a pathway implicated in cardiovascular and neuroinflammatory disease.
The company’s current commercialization strategy is centered on peripheral artery disease, or PAD, which it says affects an estimated 20 million U.S. adults. Rezera also has a neuroinflammation program, giving it two shots on goal in inflammation-linked disease areas, but both remain in development rather than in market. The company was formed as NodThera Ltd. in 2016 and is based in Boston.
The broader market backdrop is attractive but crowded. Rezera is targeting residual inflammatory risk in cardiovascular disease, where the filing points to growing interest in anti-inflammatory approaches and guideline support for certain therapies in PAD and ASCVD. At the same time, it faces competition from pathway rivals in IL-1β and IL-6, plus a range of direct NLRP3 developers in neuroinflammation, including large pharma and biotech names.
Why They're Going Public
Rezera says the IPO is meant to fund the next stage of development for ruvonoflast, especially its proposed Phase 3 PAD trial, with topline data expected in 2028. At the midpoint price of $12.00 per share, the company estimates net proceeds of $181.0 million, or $208.9 million if the underwriters fully exercise their option.
The company plans to use the money for the PAD program and general corporate purposes. If proceeds come in above expectations, Rezera says it expects to direct some of the extra capital toward the trabzanoflast trial. Going public also gives the company a larger capital base as it moves from early clinical work toward a much more expensive late-stage development phase.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
Rezera has not generated revenue to date and does not expect product revenue in the near future. That means the financial story is still about burn rate, pipeline progress, and runway rather than sales growth. The company reported a net loss of $42.2 million in 2025, compared with $25.2 million in 2024, while net loss attributable to common stockholders widened to $53.5 million from $33.1 million.
Spending is rising as the pipeline advances. Research and development expense increased to $31.4 million in 2025 from $16.8 million in 2024, while general and administrative expense rose to $9.6 million from $6.6 million. Cash and cash equivalents were $3.9 million as of June 30, 2026, down from $28.6 million at December 31, 2025. The filing says existing cash plus July 2026 financing would fund operations only into January 2027 without the IPO proceeds, while the offering is expected to extend runway into the first quarter of 2029.
Risk Factors
The biggest risk is the usual one for clinical-stage biotech: Rezera has no revenue, no approved product, and no assurance that its programs will ever reach commercialization. The company itself says drug development is highly speculative, and it has not yet tested its PAD program in PAD patients, which leaves a major clinical and regulatory question still unanswered.
Investors also need to watch dilution and execution risk. The offering leaves 146,803,003 shares outstanding before option exercise, and the filing says 16,666,667 shares will be freely tradable immediately after the offering, assuming no insider purchases. The lock-up period is 180 days, so supply could increase later. Competition is another issue: Rezera is up against other inflammation and NLRP3 programs, including larger and better-capitalized companies, and the company’s path to approval will likely require clean late-stage data in a market where alternatives are already being explored.
Comparable Public Companies
The closest public comps are other early-stage inflammation and immunology names. Ventyx Biosciences (VTYX) is a relevant NLRP3-adjacent peer and has been volatile, which is typical for development-stage biotech. Inflarx (IFRX) is another early inflammation name with a similar risk profile. Aclaris Therapeutics (ACRS) offers a broader immunology comparison, while Arcutis Biotherapeutics (ARQT) is a more commercial-stage benchmark in inflammation-related biotech. Sutro Biopharma (STRO) is less direct scientifically, but it helps frame how the market treats pre-commercial biotech with ongoing R&D spend.
The comp set looks mixed rather than hot. These names generally trade on pipeline news, clinical readouts, and cash runway rather than revenue multiples, so valuation swings can be sharp. Based on recent sector behavior, the group has been volatile over the last 6 to 12 months, with no clear uniform rerating across the space. That makes Rezera’s pricing more about investor appetite for a late-stage inflammation story than about a clean public-market benchmark.
Verdict
Rezera is a classic pre-revenue biotech IPO: the story is compelling if you believe NLRP3 inhibition can translate into meaningful clinical benefit in PAD and beyond, but the company still has to prove that its lead program works in the patients it wants to treat. As it prices, shareholders should watch how the market values the combination of a large PAD opportunity, a wholly owned pipeline, and the fact that the company is still years away from topline Phase 3 data.
The timing angle matters because this is a development-stage biotech listing into a market that tends to reward differentiated science when the sector is open, but punishes uncertainty when risk appetite is thin. Rezera’s narrative is noteworthy right now because it sits at the intersection of cardiovascular inflammation, a large unmet-need PAD market, and a relatively limited competitive field in that specific indication. The setup favors investors who are comfortable underwriting clinical execution risk in exchange for exposure to a potentially differentiated anti-inflammatory platform.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
